Autologous Hematopoietic Stem Cell Transplantation in Autoimmune Diseases

Claudio Annaloro; Francesco Onida; Giorgio Lambertenghi Deliliers


Expert Rev Hematol. 2009;2(6):699-715. 

In This Article

Five-year View

The ongoing controlled clinical trials are expected to address the major questions concerning the indications and benefits of autologous HSCT in ADs, enabling the referral for transplantation patients with a favorable risk–benefit profile in each setting of AD. Autologous HSCT has been explored in ADs as a means of overcoming autoimmunity through a reconditioning of the immune system. In the field of cellular therapy, mesenchymal cell transplantation, bearing the potential of switching off autoimmunity, might become an effective alternative to autologous HSCT, notably in the varieties of ADs deriving a limited benefit, if any, from HSCT.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.